Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ahoulihan15
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ahoulihan15
-
In case you forget where we’ll be this week.https://twitter.com/macbiocom/status/1217193188395491329 …
0:06Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Only packing the essentials for the big MacDougall office move.https://twitter.com/macbiocom/status/1187806157466996743 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amanda Houlihan proslijedio/la je Tweet
Dr. Tatiana Novobrantseva just shared what we've been working on
@verseau_tx at#MDTS19 . To catch up on our recent announcements, visit https://www.verseautx.com/news/ .#biotech#verseautxpic.twitter.com/aeEn7tt39s
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you to
@HansonWade for putting on the Macrophage-directed Therapies Summit. A great first day!#MDTS19 https://macrophage-directed-therapies.com/ pic.twitter.com/1hqmgyLZwu
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
For the last event of day one at the Macrophage-directed Therapies Summit Kipp Weiskopf, Whitehead Fellow,
@WhiteheadInst and Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation,@Boehringer will lead an audience discussion.#MDTS19Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
One more networking break before we head into the final presentation for day one of the Macrophage-directed Therapies Summit.
#MDTS19Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Philip Brandish, Senior Principal Scientist,
@Merck is up next presenting "Therapeutic Approaches & Basic Research on Myeloid Immune Suppression in the Tumor Microenvironment" at the Macrophage-directed Therapies Summit here in#Boston.#MDTS19https://www.merck.com/index.htmlHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Jennifer Guerriero, Director, Breast Immunology Laboratory
@DanaFarber is presenting "Targeting Macrophages for Anti-cancer Therapy" at the Macrophage-directed Therapies Summit. …https://breasttumorimmunologylab.dana-farber.org/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@macrophagepharm's ESM technology targets small molecule drugs to macrophages.#MDTS19Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Søren Bregenholt, CEO of
@MacrophagePharm is up next to present "Regulating Macrophage Polarization to Create a Tumor Suppressive Environment".#MDTS19http://www.macrophagepharma.com/Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"In both primary human cell assays and ex vivo tumors PSGL-1 works as a monotherapy and can add to PD1 therapy activity, with potential to expand IO response" - Novobrantseva,
@verseau_tx#MDTS19Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Novobrantseva tells the crowd, the "first target we have unblinded is PSGL-1." "PSGL-1 is a cell surface receptor involved in adhesion and immune modulation."
@verseau_tx#MDTS19Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
When identifying targets Novobrantseva says that
@verseau_tx uses an all human translational platform and "starts with target discovery from human tumors."https://www.verseautx.com/science/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Novobrantseva says that "only about a quarter of human cancers respond to t cell engaging immunotherapies."
@verseau_tx "aims to develop therapies that modulate macrophages."#MDTS19Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@verseau_tx announced their company launch on Monday.@AmberTongPW tells the story of Verseau's founding and approach to developing#macrophage targeted therapeutics in this article in@endpts.#MDTS19https://endpts.com/armed-with-langer-tech-and-50m-verseau-hails-new-checkpoint-drugs-unleashing-macrophages-against-cancer/ …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Back from lunch and getting ready for
@verseau_tx Co-founder and CSO Tatiana Novobrantseva's presentation "Completing the Immunity Cycle by Developing Macrophage Immunotherapies".#MDTS19https://www.verseautx.com/Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Taking a quick break for lunch and then it’s back to more presentations on
#macrophage therapies at the Macrophage-directed Therapies Summit.#MDTS19Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Brie Perell says that
@biotechne, a leading developer and manufacturer of high-quality purified proteins and reagent solutions, is "focusing in on how we can leverage some of these competencies in the macrophage therapeutics space".#MDTS19Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Brie Perell of
@biotechne is presenting on "Incorporating Novel Tools to Enhance Ex Vivo Cell Manufacturing Workflows" at the Macrophage-directed Therapies Summit#MDTS19https://www.bio-techne.com/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.